PAP
STRO icon

Persistent Asset Partners’s Sutro Biopharma STRO Stock Holding History

Persistent Asset Partners’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Sell
6,569
-842
-11% -$26.3K 0.07% 204
2026
Q1 		$185K Buy
+7,411
New +$134K 0.07% 203

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Persistent Asset Partners's STRO Position: Q2 2026 in Review

Persistent Asset Partners reduced its Sutro Biopharma (STRO) stake by 11% in Q2 2026, selling an estimated $26.3K and leaving 6,569 shares worth $218K. The position accounts for 0.07% of the portfolio, ranked #204.

Persistent Asset Partners first reported a position in STRO in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Persistent Asset Partners held 6,569 shares of Sutro Biopharma worth $218K as of Q2 2026.
  • Persistent Asset Partners sold 842 Sutro Biopharma shares in Q2 2026, an estimated $26.3K.
  • Sutro Biopharma made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #204 holding.
  • Persistent Asset Partners first reported a position in Sutro Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.